Summary of Key Information:

Reporting Period: Quarter and Financial Year ended March 31, 2026

Nature of Filing / Announcement: Outcome of Board Meeting and Financial Results Disclosure

Audit Opinion:

Unmodified opinion issued by S K Patodia & Associates LLP, Chartered Accountants

Key Financial Highlights [All amounts in ₹ millions]:

Consolidated Results:

Quarter Ended March 31, 2026:

  • Revenue from Operations: 1,150.41
  • Total Income: 1,189.96
  • Net Profit: 109.04
  • EPS Basic: 0.99
  • EPS Diluted: 0.89

Year Ended March 31, 2026:

  • Revenue from Operations: 3,826.28 (vs 3,249.29 in FY25)
  • Total Income: 3,945.66 (vs 3,312.87 in FY25)
  • Net Profit: 379.37 (vs 243.05 in FY25)
  • EPS Basic: 3.43 (vs 1.75 in FY25)
  • EPS Diluted: 3.09 (vs 1.75 in FY25)
  • Other Equity: 2,222.30
  • Cash and Cash Equivalents: 157.74
  • Total Debt: 196.11 (Short-term: 137.93, Long-term: 58.18)

Standalone Results:

Quarter Ended March 31, 2026:

  • Revenue from Operations: 984.71
  • Total Income: 1,046.21
  • Net Profit: 136.33
  • EPS Basic: 1.23
  • EPS Diluted: 1.11

Year Ended March 31, 2026:

  • Revenue from Operations: 3,191.20 (vs 2,674.47 in FY25)
  • Total Income: 3,343.34 (vs 2,775.29 in FY25)
  • Net Profit: 381.48 (vs 269.69 in FY25)
  • EPS Basic: 3.45 (vs 1.99 in FY25)
  • EPS Diluted: 3.10 (vs 1.99 in FY25)
  • Other Equity: 2,202.73
  • Cash and Cash Equivalents: 97.65
  • Total Debt: 241.41 (Short-term: 211.47, Long-term: 29.94)

Segment-wise Performance:

The company operates in a single business segment: "manufacturing of nutritional products" as per Ind AS 108.

Corporate Actions:

  • No dividend declared for the period
  • Completed conversion of Compulsorily Convertible Preference Shares (CCPS) into equity shares on April 20, 2026
  • Completed IPO through 100% Offer for Sale of 3,08,59,704 equity shares at ₹45 per share (aggregating ₹138.87 crores) on June 12, 2026
  • Company did not receive any proceeds from the IPO as it was entirely an Offer for Sale

Other Significant Information:

  • The amalgamation was accounted under Pooling of Interests Method
  • Comparative figures have been restated due to the amalgamation
  • Two foreign subsidiaries (South Africa and Uzbekistan) showed operational recovery with net profits but have historical accumulated losses
  • Holding company provided unconditional financial support guarantee for foreign subsidiaries
  • The figures for quarters ended December 31, 2025 and March 31, 2025 were not subjected to review or audit as quarterly review requirement applied only from Q4 FY26 post-listing